The head offices of Valeant Pharmaceuticals  in Laval, Quebec. The Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile in the battle for control of its US rival. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53 billion offer was rejected by the mak(...)